Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-06-25T23:08:20.849Z Has data issue: false hasContentIssue false
  • English
  • Français

Prognostic factors of primary brain metastasis from SCLC treated by whole-brain radiotherapy

Published online by Cambridge University Press:  19 October 2020

Yukinori Okada Open the ORCID record for Yukinori Okada [Opens in a new window] ,
Mariko Kobayashi ,
Mio Shinozaki ,
Tatsuyuki Abe  and
Naoki Nakamura
Yukinori Okada*
Affiliation:
Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Mariko Kobayashi
Affiliation:
Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Mio Shinozaki
Affiliation:
Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Tatsuyuki Abe
Affiliation:
Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Naoki Nakamura
Affiliation:
Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
*
Author for correspondence: Yukinori Okada, Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan. Tel: +81 44 977 8111. Fax: +81 44 977 8111. E-mail: igaueno512@yahoo.co.jp
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Small-cell lung cancer (SCLC) has poor prognosis owing to the high risk of distant metastasis.

Purpose:

To identify the prognosticators of brain metastasis from SCLC treated by whole-brain radiotherapy.

Material and methods:

We evaluated patients diagnosed with primary brain metastasis from SCLC between 1 January 2010 and 30 September 2019. Age, sex, disease stage at the first examination, time to the diagnosis of brain metastasis, state of other lesions at the diagnosis of brain metastasis, haematological parameters, neurologic symptoms, whole-brain radiotherapy dose, imaging findings of the brain metastasis (single or multiple), and chemotherapy and radiotherapy status were investigated for correlations with survival from the diagnosis of brain metastasis.

Results:

A total of 24 participants were evaluated. After radiotherapy, the median survival period was 118·5 (22–998) days, and 21 patients died during the follow-up period. Multivariate stepwise analysis of the four parameters of lactate dehydrogenase (LDH) level (within vs. above the reference value), platelet level (continuous variable), neurologic symptoms (with versus. without), and NSE (neuron-specific enolase) level (continuous variable) identified the following significant differences: neurologic symptoms were 3·81 (95% CI 1·07–13·5, p = 0·04), and NSE was 1·01 (95% CI 1·00–1·01, p = 0·04).

Conclusion:

NSE and neurologic symptoms are prognosticators of brain metastasis from SCLC treated by whole-brain radiotherapy.

Keywords

brain metastasissmall-cell lung cancer (SCLC)whole-brain irradiation
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 21 , Issue 1 , March 2022 , pp. 21 - 25
Check for updates
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rudolf, MH, Amanda, T. Update on small cell lung cancer management. Breathe 2012; 8: 314–330.Google Scholar
Govindan, R, Page, N, Morgensztern, D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539–4544.CrossRefGoogle ScholarPubMed
Byers, LA, Rudin, CM. Small cell lung cancer: where do we go from here? Cancer 2015; 121: 664–672.10.1002/cncr.29098CrossRefGoogle Scholar
Van Meerbeeck, JP, Fennell, DA, De Ruysscher, DK. Small cell lung cancer. Lancet 2011; 378: 1741–1755.CrossRefGoogle ScholarPubMed
Micke, P, Faldum, A, Metz, T et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer: what limits limited disease? Lung Cancer 2002; 37: 271–276.CrossRefGoogle Scholar
Lassen, U, Osterlind, K, Hansen, M et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13: 1215–1220.10.1200/JCO.1995.13.5.1215CrossRefGoogle Scholar
Quan, AL, Videtic, GM, Suh, JH. Brain metastases in small cell lung cancer. Oncology (Williston Park) 2004; 18: 961–972.Google ScholarPubMed
Castrucci, WA, Knisely, JP. An update on the treatment of CNS metastases in small cell lung cancer. Cancer J 2008; 14: 138–146.10.1097/PPO.0b013e318172d6e1CrossRefGoogle ScholarPubMed
Anami, S, Doi, H, Nakamatsu, K et al. Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy. J Radiat Res 2019; 60: 257–263.10.1093/jrr/rry107CrossRefGoogle ScholarPubMed
Bernhardt, D, Adeberg, S, Bozorgmehr, F et al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol 2017; 134: 205–212.CrossRefGoogle ScholarPubMed
Yang, X, Wang, D, Yang, Z et al. CEA is an independent prognostic indicator that is associated with reduced survival and liver metastases in SCLC. Cell Biochem Biophys 2011; 59: 113–119.CrossRefGoogle ScholarPubMed
Albain, KS, Crowley, JJ, LeBlanc, M et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563–1574.CrossRefGoogle Scholar
Wen, Q, Meng, X, Xie, P et al. Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy. Oncotarget 2017; 8: 81405–81418.CrossRefGoogle ScholarPubMed
Bremnes, RM, Sundstrom, S, Aasebø, U et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39: 303–313.CrossRefGoogle ScholarPubMed
Yip, D, Harper, PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000; 28: 173–185.10.1016/S0169-5002(00)00105-7CrossRefGoogle ScholarPubMed
Sculier, JP, Feld, R, Evans, WK et al. Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol 1985; 3: 1349–1354.CrossRefGoogle ScholarPubMed
Lokich, LL. Plasma CEA levels in small cell lung cancer: correlation with stage, distribution of metastases, and survival. Cancer 1982; 50: 2154–2156.3.0.CO;2-J>CrossRefGoogle Scholar
Shepherd, FA, Ginsberg, R, Patterson, GA et al. Is there ever a role for salvage operations in limited small-cell lung cancer? J Thorac Cardiovasc Surg 1991; 101: 196–200.10.1016/S0022-5223(19)36752-2CrossRefGoogle ScholarPubMed
Tian, Z, Liang, C, Zhang, Z et al. Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis. World J surg Oncol 2020; 18: 116.CrossRefGoogle ScholarPubMed
Shibayama, T, Ueoka, H, Nishii, K et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001; 32: 61–69.CrossRefGoogle Scholar
Sakin, A, Yasar, N, Arici, S et al. Effect of pretreatment platelet parameters on survival in limited disease small cell lung cancer. Asian Pac J Cancer 2019; 20: 1879–1885.10.31557/APJCP.2019.20.6.1879CrossRefGoogle ScholarPubMed